Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised USD $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure. The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging. Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.
MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments using clinical biomarkers.
Portage Pharmaceuticals
Acquisition in 2021
Portage Pharmaceuticals LTD. is developing innovative cell permeable peptide (CPP) therapies to normalize gene expression, restore protein function, and improve medical outcomes. The Company has spun out its lead asset, PPL-003, to ophthalmic indications and has licensed this CellPorter technology to EyGen, a new ophthalmic company.
LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.
LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.
Souvien Therapeutics
Venture Round in 2019
Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
BYOMass
Venture Round in 2019
BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.
BHB Therapeutics
Venture Round in 2019
BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease.
AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. The company utilizes its proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create potential treatments for age-related conditions. Its primary candidates in development include AGEX-BAT1, a cell therapy targeting metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug formulation intended to enhance regenerative capabilities in aged tissues. The company also offers human embryonic stem cells and tools for genomic interpretation through its GeneCards Database Suite. AgeX collaborates with research institutions, including the University of California, Irvine, on projects related to neurological disorders. Founded in 2017 and based in Alameda, California, AgeX aims to tackle significant challenges in the field of aging and regenerative medicine.
Napa Therapeutics
Venture Round in 2018
Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target.
FoxBio
Venture Round in 2018
FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.
AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. The company utilizes its proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create potential treatments for age-related conditions. Its primary candidates in development include AGEX-BAT1, a cell therapy targeting metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug formulation intended to enhance regenerative capabilities in aged tissues. The company also offers human embryonic stem cells and tools for genomic interpretation through its GeneCards Database Suite. AgeX collaborates with research institutions, including the University of California, Irvine, on projects related to neurological disorders. Founded in 2017 and based in Alameda, California, AgeX aims to tackle significant challenges in the field of aging and regenerative medicine.
LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.